Recorded Webinar
Speaker: Andrew Ruplin, PharmD
Multiple treatment options currently exist for patients with metastatic castration-sensitive prostate cancer (mCSPC). This webinar will review the currently approved treatment options for mCSPC, evidence-based guidelines to inform practice, and how shared decision-making can be helpful when discussing treatment choices with patients.
This activity was developed by ONS through an educational grant from Astellas and Pfizer Inc. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.